Boston Scientific today reported first-quarter financial results that came in ahead of the Wall Street forecast.

Boston Scientific (NYSE:BSX) stock has taken a beating in 2026 after management cut full-year guidance on Wednesday. On ...

Boston Scientific reported first-quarter 2026 revenue of $5.20 billion, up 11.6% year over year and slightly above expectations, with adjusted EPS of $0.80. Despite the beat, the company lowered its ...

On January 12, 2026, Boston Scientific Corporation (NYSE:BSX) shared an expansion update, announcing a definitive agreement to acquire Valencia Technologies. With this move, the company expands its ...

CEO Mike Mahoney told investors that the lowered forecast reflects challenges for several businesses, including ...

Q1 2026 Management View "First quarter represented a solid quarter for Boston Scientific with total company organic sales growth of 9.4% versus our guidance range of 8.5% to 10%." (Chairman, President ...

Boston Scientific recently received FDA 510(k) clearance for its Asurys Fluid Management System, strengthening its StoneSmart ...

Boston Scientific Corp. plans to acquire Valencia Technologies Corp. in the first half of 2026 in a move that will expand its urology portfolio. Valencia makes the Ecoin system, an implantable tibial ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost of doing business this year, according to the company’s estimates—it ...